Efficacy and Safety of Trastuzumab-rezetecan in HER2-Expressing Breast Cancer

NCT07358182 · clinicaltrials.gov ↗

RECRUITING

Status

300

Enrollment

OTHER

Sponsor class

Conditions

Trastuzumab-rezetecan
HER2-low Breast Cancer
HER2-positive Breast Cancer

Interventions

DRUG: Trastuzumab-rezetecan Treatment Group

Sponsor

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University